Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review by Polido-Pereira, J et al.
CASE BASED REVIEW
Primary biliary cirrhosis in a rheumatoid arthritis patient
treated with rituximab, a case-based review
Joaquim Polido-Pereira & Ana Maria Rodrigues &
Helena Canhão & Fernando Saraiva &
José Alberto Pereira da Silva & João Eurico Fonseca
Received: 6 September 2011 /Revised: 26 September 2011 /Accepted: 12 October 2011
# Clinical Rheumatology 2011
Abstract Primary biliary cirrhosis (PBC) is an autoim-
mune disease in which intrahepatic bile ducts are targeted
by an immune-mediated injury. This disease tends to
progress to fibrosis and cirrhosis with hepatic failure. The
authors report a case of a 50-year-old rheumatoid arthritis
(RA) patient, with erosions and seropositive for rheumatoid
factor and anti-citrullinated peptide antibodies, with
18 years disease duration refractory to prednisolone and
several disease-modifying antirheumatic drugs, either con-
ventional or biological (adalimumab and etanercept). In
April 2007, she started therapy with rituximab (RTX) with
good European League Against Rheumatism response
achieved 9 months later. In June 2008, she was admitted
with intrahepatic cholestasis, steatorrhea, and spontaneous
fractures of various ribs. After excluding cholelitiasis, as
well as infectious and neoplastic diseases a liver biopsy was
performed that was compatible with the diagnosis of PBC.
The antinuclear antibodies (1/160) were positive as well as
the antimitochondrial antibodies (1/640). Other antibodies
were negative such as anti-SSA and anti-SSB. Afterwards,
the patient started ursodesoxycholic acid 15 mg kg-1 day-1
with progressive improvement of cholestatic markers. A
labial salivary gland biopsy was performed and showed
findings compatible with the concomitant diagnosis of
Sjögren’s syndrome. Based on this clinical report, a detailed
review of the clinical aspects of PBC is presented as well as
its association with other immune-mediated inflammatory
diseases, particularly, with RA.
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Introduction
Primary biliary cirrhosis (PBC) is a chronic autoimmune
liver disease characterized by the slow progressive destruc-
tion of small bile ducts leading to cholestasis. This chronic
non-suppurative cholangitis is immune mediated by CD4+
and CD8+ T cells, anti-mitochondrial antibodies, innate
immunity, and IgA transcytosis.
PBC is more frequent in women and it is usually
diagnosed by the fourth and fifth decades of life [1–3].
Common disease manifestations are asthenia, chronic
pruritis, digestive malabsorption, xanthelasma, and jaun-
dice. However, some studies suggest that in more than half
of the patients, the diagnosis is established at an asymp-
tomatic stage [4]. Other disease manifestations include
metabolic bone disease, such as osteomalacia and osteope-
nia, which are likely secondary to the malabsorption. Lab
manifestations include moderate to high elevation of
alkaline phosphatase (ALP) and gamma glutamyltransfer-
ase (GGT), as well as mild transaminases elevation.
Bilirubin is usually normal during the early phase of the
disease. The presence of anti-mitochondrial antibodies
increase the likelihood of the diagnosis, but liver histology
is critical to ascertain the diagnosis. Ludwig and Scheuer
established four histological stages: portal damage, peri-
portal damage, septal damage, and cirrhosis [5]. Early
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diagnosis of this disease is of outmost relevance since early
treatment with ursodeoxycholic acid has proven to be
effective in decreasing liver-related mortality as well as the
need for liver transplantation [6]. Of note, PBC can be
associated with many other autoimmune diseases, such as
Sjögren’s syndrome (SS), Raynaud syndrome, autoimmune
thyroid disease, and systemic sclerosis. In fact, 70% of the
PBC patients have sicca syndrome [7–11].
The association of PBC with rheumatoid arthritis (RA) is
less clear, although several studies since the 1970s point to
a possible association; however, the true prevalence of PBC
in RA is not well known, and this may impose several
therapeutic and diagnostic challenges as we will demonstrate
in this paper [12, 13].
Case report
This case report refers to a 50-year-old patient who was
diagnosed with RA in 1990, when she was 32 years old.
She presented with 2 years disease duration of symmetric
additive polyarthritis involving proximal interphalangeal
and metacarpophalangeal joints, wrists, shoulders, knees,
ankles, tarsus, and metatarsophalangeal joints, with over
2 h of morning stiffness. She was rheumatoid factor
positive (80 IU μl−1) and had discrete erosions identified
in some metacarpophalangeal joints after 2 years of disease
duration. She also referred xerostomia, xerophtalmia, and
occasional aphtous ulcers. Antinuclear antibodies (including
SSA and SSB) were negative, and there was no evidence of
keratoconjuctivitis sicca.
She was subsequently treated with several consecutive
disease-modifying antirheumatic drugs (DMARDs), start-
ing with sulphasalazine up to 1.5 gday−1 that had to be
stopped due to nausea and vomiting. She was also treated
with prednisolone 5–10 mg day−1. In 1992, she started gold
salts, but had to be interrupted in March 1994 due to
aphtous stomatitis. In the meantime, several steroid intra-
articular injections were performed (right wrist, second and
third metacarpophalangeal joints). In 1995, she started
therapy with methotrexate (MTX) up to 7.5 mg week−1,
and hydroxychloroquine (HCQ) 400 mg day−1 was added
subsequently. MTX was also suspended in 1997 due to
mucositis. As an alternative to MTX, azathioprine (AZA)
was started in a dose up to 100 mg day−1 in December
1997. Despite this therapy, she maintained high disease
activity (DAS28 of 6.38). She received concomitant
treatment with calcium and vitamin D, and as the bone
densitometry showed a T-score of −2.26 in the hip and −1.98
in the lumbar spine, she was started on alendronate
70 mg week−1 in 2003.
In April 2003, due to sustained high disease activity,
she was medicated with adalimumab (ADA) 40 mg
every other week, maintaining AZA, HCQ, and predni-
sone. As the patient had only a partial response, AZA
was replaced by MTX 7,5 mg week−1, in June 2004.
However, DAS28 was persistently above 5.2, and she was
switched to etanercept in March 2006. Unfortunately, the
same pattern of high disease activity persisted under
etanercept and she was then proposed for treatment with
RTX 1,000 mg 2 weeks apart, which was started in April
2007. B cell depletion was confirmed. A year later, she
was with low disease activity.
In June 2008, she was admitted due to a new onset
asthenia, adinamia, and weight loss, as well as slight
fever (maximum axillary temperature of 38°C), steator-
rhea, and an episode of spontaneous posterolateral right
thoracic pain. The physical examination was unremark-
able, except for several skin excoriations, and tender
palpation of four consecutive right ribs (from fifth to
eight). She had elevated GGT (268 IU l−1, seven times
upper limit of normal) and ALP (403 IU l−1, four times
upper limit of normal). ALP bone isoenzyme was only
borderline high (34.8 μg l−1; N<22.5), despite the
fractures. Serum calcium, phosphorus, parathyroid hor-
mone, TSH, and immune electrophoresis were normal.
Cultures were negative. By this time, B cells had already
repopulated peripheral blood. The chest radiograph
showed fractures of four consecutive ribs. Abdominal
ultrasound was compatible with hepatic steatosis. The
investigation regarding occult neoplasia was negative and
the patient was dismissed. At that time, a bone densitom-
etry was repeated and showed a T score of −2.4 in the hip
and −2.2 in the lumbar spine. A few months later, the
patient was readmitted due to multiple fractures (including
a fragility wrist fracture), progressive weight loss (about
20 kg in 6 months), severe steatorrhea, and cholestasis.
Reevaluation showed a pseudopolypoid lesion of the
duodenum. The biopsy was compatible with ganglioneur-
oma. However, this finding was not considered to be
related with cholestasis, since the endoscopic retrograde
cholangiopancreatography was normal and the abdominal
ultrasound showed no biliary dilation. The patient had
intrahepatic cholestasis, with very high ALP and GGT,
mildly elevated levels of TGP and TGO, and elevated
IgM. Serum calcium and phosphorus levels were again
normal. These clinical and biochemical features were
suggestive of PBC, and a liver biopsy was performed
which showed findings compatible with this diagnosis,
Ludwig’s stage 3. Besides, at this time point, antimito-
chondrial antibodies were positive in high titer (1/640),
which further supported this hypothesis. She had also
positive antinuclear antibodies (1/160), with negative anti-
double stranded DNA (anti-dsDNA), anti-SSA, and anti-
SSB. Ursodiol therapy was started with progressive
improvement of the cholestasis markers. A salivary labial
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biopsy was performed that showed focal lymphocytic
sialadenitis, suggesting SS. A hand ultrasound was
performed that confirmed the existence of erosions in
several metacarpophalangeal joints and wrists and no
synovitis; at that time, the patient was also anti-
citrullinated peptide antibodies (ACPA)-positive (178
EU). A couple of months later, the patient was submitted
to partial duodenopancreatectomy, and the diagnosis of
ganglioneuroma was confirmed.
Reviewing the patient chart, there were previous
episodes of elevation of cholestatic markers (ALP and
GGT) which were always self-limited, asymptomatic. and
interpreted as drug-induced events.
In March 2010, due to disease reactivation, the patient
was retreated with RTX, but this time without any clinical
significant response. A further switch to abatacept was
tried, but currently, RA remains active. CBP manifestations
are quiescent.
Discussion
This case report illustrates the association of multiple
immune-mediated diseases and the therapeutic chal-
lenges which this scenario arises. This patient had a
classic, established RA with almost 20 years of disease
duration and was exposed to multiple DMARDs, ending
with RTX after failing two TNF inhibitors. In fact, there
was a clinically significant response (good European
League Against Rheumatism response), but when the
patient was going to be retreated she was admitted due
to severe cholestasis and multiple rib fractures. Chronic
cholestasis seemed to explain bone fragility, but the
atypical rib fractures forced the work out for an occult
neoplasia. Bone metabolic disturbances induced by
long-standing RA, chronic corticosteroid treatment, and
prolonged exposure to biphosphonates might have
contributed for the atypical pattern of bone fragility,
initially dominated by multiple rib fractures. In the
absence of biliary tree dilation, the investigation had to
rely on causes of intrahepatic cholestasis. The clinical
presentation and the fact that there were very high
levels of ALP and GGT, mildly elevated AST and ALT,
and high IgM suggested the diagnosis of PBC, which
was confirmed after compatible serology and liver
biopsy. After reviewing the patient’s chart, there were
previous episodes of cholestasis which seemed to be
drug-induced; they were always mild to moderate and
self-limited. After 1 year of RTX treatment, severe
intrahepatic cholestasis surfaced, and interestingly, this
event was coincident with B cell repopulation.
Hepatic involvement of most rheumatic diseases is
common and usually related with nonspecific findings
(drug-related most of the times). However, more serious
hepatic involvement, including vasculitis, nodular regen-
erative hyperplasia, and primary biliary cirrhosis, have
been observed in specific rheumatic diseases, such as RA
[14, 15].
Furthermore, ALP elevations in RA are common and
rarely related with PBC [16]. In a recent review of 607
patients with diffuse connective tissue diseases, liver
dysfunction was observed in 38.2% and PBC was present
in 15.9%. This review showed that in scleroderma and SS,
PBC was the cause of liver dysfunction in above 70% of
the patients, which did not occur in RAwhere cases of PBC
were rare (3 out of 220 patients) [17].
RA is present in about 1% of the population and PBC is
even rarer, with an estimated prevalence of 20/100,000 for
woman and 2/100,000 for men and the association of both
diseases by chance is very unusual [10]. However, there are
some reports describing its association in individuals or
families [18, 19]. Few studies have suggested an increased
prevalence (1.8% and 5.6%) of RA in PBC patients as
compared to the prevalence in the general population [4,
20, 21]. In one series of 42 patients with PBC, four
presented symptomatic arthritis with rheumatoid factor
positivity, and nine had erosions without symptomatic
arthritis [22]. In another series, 4 out of 83 patients with
PBC presented inflammatory arthritis [23]. In a Japanese
review, 3 of the 54 patients with PBC had polyarthritis,
without specifying whether or not RA criteria were fulfilled
[24]. In a 1980s review of 26 PBC patients, 7 were
classified as RA, which seems an overestimation [25]. On
the contrary, a recent review of 278 patients with
autoimmune hepatitis (some of them overlapping with
PBC), 111 had concurrent autoimmune diseases, of which
only 5 had RA, according to the ACR 1987 ARA
diagnostic criteria [26].
Currently, there is no accurate estimate of PBC
prevalence in RA patients but several studies estimated
that 10–18% of these patients have antimitochondrial
antibodies, which have indeed a high association with
PBC. Importantly, most of these patients had associated
syndromes, as was the case of our patient. On the other
hand, approximately half of the patients with PBC
become rheumatoid factor positive during the course of
the disease [27–29]. In fact, in an older series, 70% of the
PBC patients were rheumatoid factor positive [8].
Serology overlap also happens with ACPA. In fact,
according to Koga et al. ACPA are positive in 2.7% of
the CPB patients and in 10.5% of the autoimmune
hepatitis patients, almost always in association with a
clinical presentation compatible with concomitant RA
[30]. In another work, Santiago et al. showed that ACPA
(third generation) were present in 3.7% of the PBC
patients [31].
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Despite the low prevalence of PBC in RA patients,
auto antibodies overlap and shared genetic risk factors,
namely, related with CTLA4 and ICOS SNPs, suggest-
ing the existence of at least some common physiopath-
ological mechanisms [32]. In fact, RTX has been
proposed as a treatment option for PBC and curiously
overt clinical and laboratorial manifestations of PBC
occurred in our patient after B cell repopulation. Another
interesting and unexplored field is the disturbance of
costimulation that occurs in PBC that might benefit from
costimulation modulating therapies such as abatacept [33,
34]. However, the use of abatacept in our patient
(introduced for RA treatment) did not influence PBC
clinical manifestations.
Key points
(1) PBC is a rare disease that can appear in association
with several other immune-mediated diseases
(2) PBC’s association with RA is unclear despite some
reports in the literature suggesting a possible link
between both diseases
(3) In patients with rheumatic diseases, persistent eleva-
tion of liver enzymes, mostly with cholestatic pattern,
shall raise the suspicion of a possible PBC
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